Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Viral correlates of protection and the multifarious interactions of B and T cells.

Human vaccines & immunotherapeutics·2025
Same author

A Framework for Assessing Viral Pathogens: A Key Element of the BARDA Emerging Infectious Diseases Strategy.

Health security·2025
Same author

Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats.

Vaccines·2025
Same author

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.

Nature communications·2024
Same author

Anticipating the Next Pandemic.

The New England journal of medicine·2024
Same author

Development of Next-Generation COVID-19 Vaccines: Biomedical Advanced Research and Development Authority (BARDA-)-Supported Phase 2b Study Designs.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same journal

Tracking Synthetic Adhesins on Bacterial Surfaces with Immunofluorescence Microscopy.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Post-Selection Methods for Analyzing mRNA Display Selections and Optimization of Hits.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

High-Performance Computing in Tandem Mass Spectrometry (MS/MS) Peptide Identification.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

AI-Driven Protein Research: From Prediction to Design.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Methods for the In Vitro Selection of Protein and Peptide Libraries Using mRNA Display.

Methods in molecular biology (Clifton, N.J.)·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.3K

Marburg Virus Medical Countermeasures.

Karen A Martins1, Daniel N Wolfe2

  • 1Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC, USA. karen.martins@hhs.gov.

Methods in Molecular Biology (Clifton, N.J.)
|November 25, 2024
PubMed
Summary
This summary is machine-generated.

Licensed medical countermeasures for Ebola virus (EBOV) offer a path to develop Marburg virus (MARV) vaccines and therapeutics. Lessons from EBOV inform MARV countermeasure development and deployment strategies.

Keywords:
AntibodiesClinical trialsFilovirusMARVTherapeuticVaccine

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.7K
Merkel Cell Polyomavirus Infection and Detection
13:45

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

9.9K

Related Experiment Videos

Last Updated: Jun 6, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance
13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.3K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.7K
Merkel Cell Polyomavirus Infection and Detection
13:45

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

9.9K

Area of Science:

  • Virology
  • Epidemiology
  • Public Health

Background:

  • Marburg virus (MARV), a member of the Filoviridae family, poses a significant biological threat with no currently available licensed vaccines or therapeutics.
  • Licensed medical countermeasures (MCMs) exist for Ebola virus (EBOV), another Filoviridae family member, providing a precedent for MARV countermeasure development.

Purpose of the Study:

  • To leverage lessons learned from Ebola virus (EBOV) outbreak responses and MCM development for Marburg virus (MARV) MCM development.
  • To define the concept of operations for utilizing vaccines and therapeutics against MARV.
  • To establish target product profiles for MARV MCMs based on the operational concept.

Main Methods:

  • Reviewing lessons learned from EBOV outbreak responses and MCM development.
  • Analyzing the likely concept of operations for MARV vaccines and therapeutics.
  • Defining target product profiles informed by the concept of operations.

Main Results:

  • Identification of applicable strategies from EBOV MCM development for MARV.
  • Outlining a probable concept of operations for MARV MCM deployment.
  • Establishing target product profiles to guide MARV countermeasure advancement.

Conclusions:

  • The established EBOV MCM framework provides a viable model for accelerating MARV countermeasure development.
  • Defining operational concepts and target product profiles is crucial for advancing the MARV MCM pipeline.
  • Next steps involve progressing the current MARV MCM pipeline towards licensure.